GLPBio

Hinokitiol

Catalog No.: GC11302Purity:>98.00%Synonyms: NSC 18804, β-Thujaplicin, 4-isopropyl Tropolone
Hinokitiol هو أحد مكونات الزيوت الأساسية المعزولة من Chymacyparis obusa ، ويقلل من تعبير Nrf2 ، ويقلل DNMT1 و UHRF1 mRNA وتعبير البروتين ، مع أنشطة مضادة للعدوى ومضادة للأكسدة ومضادة للورم

المنتجات مخصصة للاستخدام البحثي فقط، وليست للاستخدام البشري. نحن لا نبيع للمرضى.


Hinokitiol
Cas No.: 499-44-5
10mM (in 1mL DMSO)In Stock
$31.00
1
50mgIn Stock
$28.00
1
100mgIn Stock
$53.00
1
500mgIn Stock
$70.00
1
1gIn Stock
$88.00
1

المراجع (Citations)

لا تتوفر حاليًا مراجع لهذا المنتج. فيما يلي مجموعة مختارة من المنشورات التي تستشهد بمنتجات GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

الوصف (Description)

Hinokitiol is a naturally occurring tropolone compound from the Formosan cypress with antibacterial and anticancer properties [1]. Hinokitiol induces oxidative stress, cytotoxicity, and autophagy through modulation of PI3K/Akt/mTOR, p38/ERK/MAPK, nuclear factor kappa B, and c-Jun N-terminal kinase signaling pathways [2]. Hinokitiol has been widely used to inhibit the metabolic processes of bacterial cell membranes, regulate respiration and membrane permeability, thereby effectively killing various bacteria[3].

In vitro, Hinokitiol treatment for 48 hours significantly reduced the cell viability of Ishikawa cells, HEC-1A cells, and KLE cells, with IC50 values of 13.33μM, 49.51μM, and 4.69μM, respectively[4]. Treatment with 30μg/ml Hinokitiol for 24 hours led to the loss of cell membrane integrity and cell cycle arrest in KB-1 cells[5]. Treatment with 40µM Hinokitiol for 24 hours blocked the process of HeLa cells transitioning from the G2/M phase to the G1 phase, increased the expression levels of p21 and p53, promoted cytoplasmic expansion and enhanced SA-β-gal activity, and induced cell senescence[6].

In vivo, Hinokitiol treatment via oral administration at a dose of 100mg/kg every other day for 3 weeks significantly reduced tumor volume and tumor weight in the HCT-116 xenograft mouse model[7]. A single intravenous injection of 1.7mg/kg dose of Hinokitiol can alleviate liver injury induced by hemorrhagic shock/resuscitation in mice within 24 hours[8].

References:
[1] El Hachlafi N, Lakhdar F, Khouchlaa A, et al. Health benefits and pharmacological properties of hinokitiol[J]. Processes, 2021, 9(9): 1680.
[2] Bhuia M S, Chowdhury R, Afroz M, et al. Therapeutic efficacy studies on the Monoterpenoid Hinokitiol in the treatment of different types of cancer[J]. Chemistry & biodiversity, 2025, 22(5): e202401904.
[3] Morita Y, Sakagami Y, Okabe T, et al. The mechanism of the bactericidal activity of hinokitiol[J]. Biocontrol Science, 2007, 12(3): 101-110.
[4] Chen H Y, Cheng W P, Chiang Y F, et al. Hinokitiol exhibits antitumor properties through induction of ROS-mediated apoptosis and p53-driven cell-cycle arrest in endometrial cancer cell lines (Ishikawa, HEC-1A, KLE)[J]. International journal of molecular sciences, 2021, 22(15): 8268.
[5] Roy A, Cheriyan B V, Perumal E, et al. Effect of hinokitiol in ameliorating oral cancer: in vitro and in silico evidences[J]. Odontology, 2025, 113(2): 750-763.
[6] Wang C C, Chen B K, Chen P H, et al. Hinokitiol induces cell death and inhibits epidermal growth factor-induced cell migration and signaling pathways in human cervical adenocarcinoma[J]. Taiwanese Journal of Obstetrics and Gynecology, 2020, 59(5): 698-705.
[7] Lee Y S, Choi K M, Kim W, et al. Hinokitiol inhibits cell growth through induction of S-phase arrest and apoptosis in human colon cancer cells and suppresses tumor growth in a mouse xenograft experiment[J]. Journal of natural products, 2013, 76(12): 2195-2202.
[8] Lu W J, Lin K H, Tseng M F, et al. New therapeutic strategy of hinokitiol in haemorrhagic shock‐induced liver injury[J]. Journal of Cellular and Molecular Medicine, 2019, 23(3): 1723-1734.

البروتوكول (Protocol)

Cell experiment [1]:

Cell lines

KLE cells

Preparation Method

KLE cells were seeded in 96-well plates at a density of 3×103 cells in DMEM/Ham’s F-12 with 10% (v/v) fetal bovine serum (FBS), 100U/ml penicillin, and 100µg/ml streptomycin in a humidified atmosphere containing 5% CO2 for 24h. After 48h of treatment with different concentrations of Hinokitiol (1, 5, 10, 25, and 50µM), the cell viability was measured.

Reaction Conditions

1, 5, 10, 25, and 50µM; 48h

Applications

Hinokitiol treatment significantly inhibited the cell viability of KLE cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

Male BALB/c-nude mice

Preparation Method

Male BALB/c-nude mice (6 weeks old; 22-25g) were housed in a room with controlled temperature (21-23°C), humidity (55-60%), and lighting (12h light/dark cycle) and were supplied with water. After being acclimated for 1 week, nude mice were randomly distributed in 3 groups: normal (n=10), HCT-116 xenograft (n=10), HCT-116 xenograft-Hinokitiol treatment (n=10). The mice were inoculated with HCT-116 cells by intradermal injection (2×106 tumor cells in 0.2ml of PBS/mouse) with a 26-gauge needle into the flank. After 2 days, mice were orally administered Hinokitiol (100mg/kg; every other day for 3 weeks). Tumor volumes were periodically measured.

Dosage form

100mg/kg; every other day for 3 weeks; p.o.

Applications

Hinokitiol treatment significantly decreased the tumor volumes in mice with HCT-116 xenografts.

References:
[1] Chen H Y, Cheng W P, Chiang Y F, et al. Hinokitiol exhibits antitumor properties through induction of ROS-mediated apoptosis and p53-driven cell-cycle arrest in endometrial cancer cell lines (Ishikawa, HEC-1A, KLE)[J]. International journal of molecular sciences, 2021, 22(15): 8268.
[2] Lee Y S, Choi K M, Kim W, et al. Hinokitiol inhibits cell growth through induction of S-phase arrest and apoptosis in human colon cancer cells and suppresses tumor growth in a mouse xenograft experiment[J]. Journal of natural products, 2013, 76(12): 2195-2202.

وثائق المنتج (Product Documents)

Purity:>98.00%Appearance:A solid

الخصائص الكيميائية (Chemical Properties)

رقم CAS
499-44-5
المرادفات
NSC 18804, β-Thujaplicin, 4-isopropyl Tropolone
الاسم الكيميائي
2-hydroxy-4-isopropylcyclohepta-2,4,6-trienone
SMILES
OC1=CC(C(C)C)=CC=CC1=O
الصيغة الجزيئية
C10H12O2
الوزن الجزيئي
164.2
الذوبانية
≥ 16.4mg/mL in DMSO
التخزين
Store at -20°C
إرشادات عامة
اختر مذيبًا مناسبًا وفقًا لبيانات ذوبانية المنتج. بعد التحضير، قسّم المحلول المخزون إلى أجزاء لتجنب دورات التجميد والذوبان المتكررة.
استخدم المحاليل المخزونة خلال 6 أشهر عند حفظها في -80°C، أو خلال شهر واحد عند حفظها في -20°C.
لتحسين الذوبانية، سخّن الأنبوب إلى 37°C وعرّضه للموجات فوق الصوتية لمدة مناسبة.
شروط الشحن
تُشحن عينات التقييم مع عبوات تبريد. وتُشحن الأحجام الأخرى المتاحة في درجة حرارة الغرفة، أو مع عبوات تبريد عند الطلب.

الحاسبات (Calculators)المولارية / التخفيف / الوزن الجزيئي / تحويل الوحدات / تركيبة داخل الجسم الحي / الذوبانية

g/mol

Reviews

Review for Hinokitiol

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%